Future perspectives for the development of P-glycoprotein modulators
Authors:
- Tito FojoTFTito Fojo
- Susan E. BatesSBSusan E. Bates
- 1 January 1998
- journal article
- Published by Elsevier in Drug Resistance Updates
- Vol. 1 (3) , 190-200
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Initial Pharmacokinetics and Bioavailability of PSC 833, a P-Glycoprotein AntagonistThe Journal of Clinical Pharmacology, 1997
- Clinical trials of p-glycoprotein reversal in solid tumoursEuropean Journal of Cancer, 1996
- Clinical multidrug resistance in cancer: A multifactorial problemEuropean Journal of Cancer, 1996
- Serum can inhibit reversal of multidrug resistance by chemosensitisersEuropean Journal of Cancer, 1996
- Drug Resistance-Associated Marker Lrp for Prediction of Response to Chemotherapy and Prognoses in Advanced Ovarian CarcinomaJNCI: Journal of the National Cancer Institute, 1995
- Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoproteinEuropean Journal of Cancer, 1993
- Various Methods of Analysis of mdr-1/P-Glycoprotein in Human Colon Cancer Cell LinesJNCI: Journal of the National Cancer Institute, 1992
- Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivoEuropean Journal of Cancer, 1992
- MDR1 gene expression and prognostic factors in primary breast carcinomasEuropean Journal of Cancer and Clinical Oncology, 1991
- The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humansAmerican Heart Journal, 1985